A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Immune globulin (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Sponsors SK Plasma
Most Recent Events
- 07 Oct 2022 New trial record